Advisory Committee on Breast Cancer in Young Women, Centers for Disease Control and Prevention: Notice of Charter Renewal, 84592 [2016-28206]
Download as PDF
<![CDATA[
84592
Federal Register / Vol. 81, No. 226 / Wednesday, November 23, 2016 / Notices
committee membership be balanced in
terms of points of view represented and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
appointed to serve on a CDC SEP and
can be full-time employees of the U.S.
Government. Current participation on
CDC federal workgroups or prior
experience serving on another federal
advisory committee does not disqualify
a reviewer, except for service on the
Board of Scientific Counselors, NCIPC.
However, HHS policy is to avoid
excessive individual service on advisory
committees and multiple committee
memberships. Reviewers appointed to
the SEP, CDC are not considered Special
Government Employees, and will not be
required to file financial disclosure
reports.
Nominees interested in serving as a
potential reviewer on a SEP, CDC for
NCIPC programs should submit the
following items:
• Current curriculum vitae, including
complete contact information (name,
affiliation, mailing address, telephone
number, and email address).
Nomination materials must be
postmarked by March 31, 2017 and sent
by U.S. mail to: NCIPC Extramural
Research Program Office (ERPO):
Centers for Disease Control and
Prevention, 1600 Clifton Road NE.,
Mailstop F–63, Atlanta, Georgia 30329
or to the ERPO Mailbox NCIPC_ERPO@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
mstockstill on DSK3G9T082PROD with NOTICES
[FR Doc. 2016–28207 Filed 11–22–16; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
18:04 Nov 22, 2016
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Breast Cancer
in Young Women, Centers for Disease
Control and Prevention: Notice of
Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Committee on Breast Cancer
in Young Women, Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS), has been renewed for a
2-year period through June 17, 2018.
For information, contact Temeika L.
Fairley, Ph.D., Designated Federal
Officer, Advisory Committee on Breast
Cancer in Young Women, HHS, CDC,
4770 Buford Highway NE., Mailstop
K52, Atlanta, Georgia 30341, telephone
770/488–4518, fax 770/488–4760.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–28206 Filed 11–22–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–D–4033]
Nonprescription Sunscreen Drug
Products—Format and Content of Data
Submissions; Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a
guidance for industry entitled
‘‘Nonprescription Sunscreen Drug
Products—Format and Content of Data
Submissions.’’ This guidance addresses
FDA’s current thinking on the format
and content of information provided to
support a request for a determination
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
whether a nonprescription sunscreen
active ingredient is generally recognized
as safe and effective (GRASE), as
provided under the Federal Food, Drug,
and Cosmetic Act (the FD&C Act), as
amended by the Sunscreen Innovation
Act (SIA).
DATES: Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: You may submit comments
as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public submit the comment as a written/
paper submission and in the manner
detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2015–D–4033 for ‘‘Nonprescription
Sunscreen Drug Products—Format and
Content of Data Submissions; Guidance
for Industry; Availability.’’ Received
comments will be placed in the docket
E:\FR\FM\23NON1.SGM
23NON1
]]>Agencies
[Federal Register Volume 81, Number 226 (Wednesday, November 23, 2016)]
[Notices]
[Page 84592]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28206]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Breast Cancer in Young Women, Centers for
Disease Control and Prevention: Notice of Charter Renewal
This gives notice under the Federal Advisory Committee Act (Pub. L.
92-463) of October 6, 1972, that the Advisory Committee on Breast
Cancer in Young Women, Centers for Disease Control and Prevention
(CDC), Department of Health and Human Services (HHS), has been renewed
for a 2-year period through June 17, 2018.
For information, contact Temeika L. Fairley, Ph.D., Designated
Federal Officer, Advisory Committee on Breast Cancer in Young Women,
HHS, CDC, 4770 Buford Highway NE., Mailstop K52, Atlanta, Georgia
30341, telephone 770/488-4518, fax 770/488-4760.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-28206 Filed 11-22-16; 8:45 am]
BILLING CODE 4163-18-P
